Financials in USD. Standardized financial statements.
A compact view of how BB Biotech AG turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $587.06M | $111.63M | -$193.76M | -$349.50M | -$395.23M | $699.23M | $685.24M | -$465.75M | $693.05M | -$796.45M |
| Revenue Growth? | +425.9% | +157.6% | +44.6% | +11.6% | -156.5% | +2.0% | +247.1% | -167.2% | +187.0% | 0.0% |
| Cost of Revenue? | $55,000 | $0 | $0 | $1.73M | $986,000 | $883,000 | $0 | $0 | $0 | $0 |
| Gross Profit? | $587.01M | $111.63M | -$199.57M | -$351.23M | -$396.22M | $699.23M | $685.24M | -$465.75M | $693.05M | -$796.45M |
| Gross Margin? | +100.0% | +100.0% | +103.0% | +100.5% | +100.2% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $8.81M | $27.23M | $6.96M | $6.52M | $8.52M | $7.98M | $685.24M | $5.52M | $5.47M | -$796.45M |
| Operating Income? | $578.20M | $84.40M | -$206.53M | -$38.62M | -$52.59M | $700.01M | $677.50M | -$36.36M | $687.58M | -$28.02M |
| EBITDA? | $578.20M | $80.24M | -$200.56M | -$351.40M | -$404.74M | $691.25M | $677.50M | -$470.02M | $687.58M | -$800.89M |
| Income Before Tax | $578.20M | $75.95M | -$206.53M | -$357.75M | -$404.74M | $691.25M | $677.50M | -$471.27M | $687.58M | -$801.99M |
| Income Tax Expense | $66,000 | $54,000 | $79,000 | $61,000 | $67,000 | $75,000 | $68,000 | $71,000 | $77,000 | $71,000 |
| Net Income? | $578.13M | $75.90M | -$206.61M | -$357.81M | -$404.81M | $691.17M | $677.43M | -$471.34M | $687.50M | -$802.07M |
| EPS? | $10.56 | $1.38 | $-3.77 | $-6.50 | $-7.31 | $12.48 | $12.23 | $-8.51 | $12.42 | $-14.51 |
| Diluted EPS? | $10.56 | $1.38 | $-3.77 | $-6.50 | $-7.31 | $12.48 | $12.23 | $-8.51 | $12.42 | $-14.51 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality